In addition, identification of other pathogenic mutations in genes with known prognostic impacts in SM (i.e., SRSF2, ASXL1, DNMT3A, RUNX1, EZH2, CBL and NRAS) should also be performed in SM patients with multilineage involvement of haematopoiesis by KIT D816V for further identification of patients at higher risk of death who may benefit from a closer follow-up and eventually, also, early cytoreductive treatment. This evidence concerns the gene SRSF2 and systemic mastocytosis.